Literature DB >> 6211135

Effect of probenecid on the pharmacokinetics of moxalactam.

K A DeSante, K S Israel, G L Brier, J D Wolny, B L Hatcher.   

Abstract

The effects of probenecid on the pharmacokinetics of moxalactam were studied in normal volunteers administered a 2-min l-g intravenous infusion. The results showed that probenecid did not alter the plasma or urinary concentrations of moxalactam, its apparent volume of distribution, plasma elimination half-life, elimination rate constant, or plasma and renal clearances. Therefore, moxalactam appears to be eliminated primarily by the kidney via glomerular filtration.

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6211135      PMCID： PMC181829          DOI： 10.1128/AAC.21.1.58

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  20 in total

1.  Linear pharmacokinetic equations allowing direct calculation of many needed pharmacokinetic parameters from the coefficients and exponents of polyexponential equations which have been fitted to the data.

Authors:  J G Wagner
Journal:  J Pharmacokinet Biopharm       Date:  1976-10

2.  CSTRIP, a fortran IV computer program for obtaining initial polyexponential parameter estimates.

Authors:  A J Sedman; J G Wagner
Journal:  J Pharm Sci       Date:  1976-07       Impact factor: 3.534

3.  Effect of probenecid on the blood levels and urinary excretion of cefamandole.

Authors:  R S Griffith; H R Black; G L Brier; J D Wolny
Journal:  Antimicrob Agents Chemother       Date:  1977-05       Impact factor: 5.191

4.  Modification of penicillin distribution and elimination by probenecid.

Authors:  M Gibaldi; D Davidson; M E Plaut; M A Schwartz
Journal:  Int Z Klin Pharmakol Ther Toxikol       Date:  1970-05

5.  GLC determination of probenecid in biological fluids.

Authors:  A G Zacchei; L Weidner
Journal:  J Pharm Sci       Date:  1973-12       Impact factor: 3.534

6.  Apparent effect of probenecid on the distribution of penicillins in man.

Authors:  M Gibaldi; M A Schwartz
Journal:  Clin Pharmacol Ther       Date:  1968 May-Jun       Impact factor: 6.875

7.  Cephaloridine activity in vitro and absorption and urinary excretion in normal young men.

Authors:  J W Kislak; B W Steinhauer; M Finland
Journal:  Am J Med Sci       Date:  1966-04       Impact factor: 2.378

8.  Effect of probenecid on serum cefoxitin concentrations.

Authors:  A J Bint; D S Reeves; H A Holt
Journal:  J Antimicrob Chemother       Date:  1977-11       Impact factor: 5.790

9.  Cephaloridine versus cephalothin: relation of the kidney to blood level differences after parenteral administration.

Authors:  S B Tuano; J L Brodie; W M Kirby
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1966

10.  The renal excretion of cephaloridine in man.

Authors:  T H Foley; N F Jones; M A Barraclough; W I Cranston; A P Hunt
Journal:  Postgrad Med J       Date:  1967-08       Impact factor: 2.401
View more
  9 in total

1.  Single- and multiple-dose pharmacokinetics of moxalactam in normal subjects.

Authors:  K S Israel; H R Black; G L Brier; J D Wolny; K A DeSante
Journal:  Antimicrob Agents Chemother       Date:  1982-07       Impact factor: 5.191

2.  Effect of probenecid on the pharmacokinetics of cefmenoxime.

Authors:  L T Sennello; D Quinn; D E Rollins; K G Tolman; R C Sonders
Journal:  Antimicrob Agents Chemother       Date:  1983-06       Impact factor: 5.191

Review 3.  Cephalosporin-probenecid drug interactions.

Authors:  G R Brown
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

4.  Pharmacokinetics of moxalactam in elderly subjects.

Authors:  M H Andritz; R P Smith; A L Baltch; P E Griffin; J V Conroy; N Sutphen; M C Hammer
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

5.  Moxalactam and piperacillin: a study of in vitro characteristics and pharmacokinetics in cancer patients.

Authors:  G L Drusano; C de Jongh; K Newman; J Joshi; R Wharton; M R Moody; S C Schimpff
Journal:  Infection       Date:  1985 Jan-Feb       Impact factor: 3.553

6.  A novel pharmacokinetic method for analysis of placental transfer of latamoxef in humans.

Authors:  T Yamamoto; J Yasuda; M Kanao; H Okada; T Oguma; H Yamada
Journal:  Clin Pharmacokinet       Date:  1986 Mar-Apr       Impact factor: 6.447

Review 7.  Moxalactam (latamoxef). A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A A Carmine; R N Brogden; R C Heel; J A Romankiewicz; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-10       Impact factor: 9.546

8.  Renal disposition of ceftazidime illustrated by interferences by probenecid, furosemide, and indomethacin in rabbits.

Authors:  C Carbon; F Dromer; N Brion; A C Cremieux; A Contrepois
Journal:  Antimicrob Agents Chemother       Date:  1984-09       Impact factor: 5.191

9.  Comparison of the pharmacokinetics of ceftazidime and moxalactam and their microbiological correlates in volunteers.

Authors:  G L Drusano; H C Standiford; B Fitzpatrick; J Leslie; P Tangtatsawasdi; P Ryan; B Tatem; M R Moody; S C Schimpff
Journal:  Antimicrob Agents Chemother       Date:  1984-09       Impact factor: 5.191
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.